Abbreviations used:NGS (Next-generation sequencing), PID (Primary immunodeficiency), WES (Whole-exome sequencing)
- Expanding the clinical and genetic spectra of primary immunodeficiency-related disorders with clinical exome sequencing: expected and unexpected findings.Front Immunol. 2019; 10: 2325
- Diagnostic impact and cost-effectiveness of whole-exome sequencing for ambulant children with suspected monogenic conditions.JAMA Pediatr. 2017; 171: 855-862
- Human inborn errors of immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee.J Clin Immunol. 2020; 40: 24-64
- Now is the time to use molecular gene testing for the diagnosis of primary immune deficiencies.J Allergy Clin Immunol Pract. 2019; 7: 833-838
- Diagnostic interpretation of genetic studies in patients with primary immunodeficiency diseases: a working group report of the Primary Immunodeficiency Diseases Committee of the American Academy of Allergy, Asthma & Immunology.J Allergy Clin Immunol. 2020; 145: 46-69
- Global overview of primary immunodeficiencies: a report from Jeffrey Modell Centers worldwide focused on diagnosis, treatment, and discovery.Immunol Res. 2014; 60: 132-144
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.Genet Med. 2015; 17: 405-424
- Genetic basis of autoimmunity.J Clin Invest. 2015; 125: 2234-2241
- Cancers related to immunodeficiencies: update and perspectives.Front Immunol. 2016; 7: 1-13
- Yield of whole exome sequencing in undiagnosed patients facing insurance coverage barriers to genetic testing.J Genet Couns. 2019; 28: 1107-1118
- Exome sequencing has higher diagnostic yield compared to simulated disease-specific panels in children with suspected monogenic disorders.Eur J Hum Genet. 2018; 26: 644-651
- Targeted NGS platforms for genetic screening and gene discovery in primary immunodeficiencies.Front Immunol. 2019; 10: 1184
- Exome sequencing covers >98% of mutations identified on targeted next generation sequencing panels.PLoS One. 2017; 12: 1-11
This study was supported by National Institutes of Health (NIH) grant number 1K08AI116979-01 (J.C.), Eleanor and Miles Shore 50th Anniversary Fellowship Award (C.D.P.), NIH grant number 1R01AI139633-01 (R.S.G.), the Samara Turkel Foundation (R.S.G.), and the Perkin Fund (R.S.G.).
Disclosure of potential conflict of interest: The spouse of C. D. Platt analyzes next-generation sequencing for Quest Diagnostics. The rest of the authors declare that they have no relevant conflicts of interest.